SG11202000484TA - Cd38 antibody - Google Patents

Cd38 antibody

Info

Publication number
SG11202000484TA
SG11202000484TA SG11202000484TA SG11202000484TA SG11202000484TA SG 11202000484T A SG11202000484T A SG 11202000484TA SG 11202000484T A SG11202000484T A SG 11202000484TA SG 11202000484T A SG11202000484T A SG 11202000484TA SG 11202000484T A SG11202000484T A SG 11202000484TA
Authority
SG
Singapore
Prior art keywords
stevenage
tusk
catalyst
international
therapeutics
Prior art date
Application number
SG11202000484TA
Other languages
English (en)
Inventor
Anne Goubier
Josephine Salimu
Corzo Beatriz Goyenechea
Pascal Merchiers
Kevin Moulder
Nina Eissler
Simone Filosto
Hemanta Baruah
Bianka Prinz
Original Assignee
Black Belt Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Black Belt Therapeutics Ltd filed Critical Black Belt Therapeutics Ltd
Publication of SG11202000484TA publication Critical patent/SG11202000484TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11202000484TA 2017-08-16 2018-08-16 Cd38 antibody SG11202000484TA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762546336P 2017-08-16 2017-08-16
US201762582609P 2017-11-07 2017-11-07
PCT/EP2018/072272 WO2019034753A1 (en) 2017-08-16 2018-08-16 ANTIBODY CD38

Publications (1)

Publication Number Publication Date
SG11202000484TA true SG11202000484TA (en) 2020-02-27

Family

ID=63259520

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202000484TA SG11202000484TA (en) 2017-08-16 2018-08-16 Cd38 antibody

Country Status (9)

Country Link
US (2) US11236173B2 (enExample)
EP (1) EP3668543A1 (enExample)
JP (1) JP7299873B2 (enExample)
KR (1) KR102770110B1 (enExample)
CN (1) CN111032086B (enExample)
AU (1) AU2018316522B2 (enExample)
CA (1) CA3072296A1 (enExample)
SG (1) SG11202000484TA (enExample)
WO (1) WO2019034753A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113727999A (zh) 2019-01-11 2021-11-30 奥默罗斯公司 用于治疗癌症的方法和组合物
WO2020185859A1 (en) 2019-03-12 2020-09-17 Arcus Biosciences, Inc. Treatment of oncogene-driven cancers
EP3947463A4 (en) 2019-03-29 2022-12-21 Arcus Biosciences, Inc. TREATMENT OF CANCER USING AN IDENTIFIED ADENOSINE FINGERPRINT
WO2021003074A1 (en) * 2019-07-03 2021-01-07 Crystal Bioscience Inc. Anti-cd38 antibody and methods of use thereof
EP4211476A4 (en) 2020-09-10 2024-11-13 CASI Pharmaceuticals, Inc. BLOOD SCREENING PROCEDURES
CN112300281B (zh) * 2020-10-29 2021-06-11 杭州爱唯生命科技有限公司 含有nk细胞的药物组合物及其治疗癌症的用途
CN114437215B (zh) * 2020-11-05 2023-02-07 上海麦济生物技术有限公司 抗人cd38抗体及其制备方法和用途
WO2025213286A1 (zh) * 2024-04-07 2025-10-16 中国医学科学院血液病医院(中国医学科学院血液学研究所) 一种阻断单核巨噬细胞功能的cd38抑制剂在治疗itp中的应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020164788A1 (en) 1994-12-02 2002-11-07 The Wellcome Foundation Limited Humanized antibodies to CD38
AU2011202520C1 (en) 2002-10-17 2016-02-18 Genmab A/S Human monoclonal antibodies against CD20
ES2541436T3 (es) 2004-02-06 2015-07-20 Morphosys Ag Anticuerpos humanos anti-CD38 y usos para ellos
AU2005235811B2 (en) 2004-02-06 2011-11-03 Morphosys Ag Anti-CD38 human antibodies and uses therefor
US9200061B2 (en) 2004-02-06 2015-12-01 Morpho Sys AG Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i
EP3312196B1 (en) 2005-03-23 2019-07-17 Genmab A/S Antibodies against cd38 for treatment of multiple myeloma
EP1888647A2 (en) 2005-05-24 2008-02-20 MorphoSys AG Generation and profiling of fully human hucal gold®-derived therapeutic antibodies specific for human cd38
PL2860192T3 (pl) * 2005-10-12 2018-03-30 Morphosys Ag Wytwarzanie i profilowanie w pełni ludzkich, uzyskanych z HuCAL GOLD terapeutycznych przeciwciał swoistych wobec ludzkiego CD38
AU2016228249A1 (en) 2006-09-26 2016-10-06 Genmab A/S Combination treatment of CD38-expressing tumors
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
AU2013209322A1 (en) 2006-10-19 2013-08-15 Sanofi-Aventis Novel anti-cd38 antibodies for the treatment of cancer
EP2097097B1 (en) 2006-12-01 2018-05-30 E. R. Squibb & Sons, L.L.C. Antibodies, in particular human antibodies, that bind cd22 and uses thereof
AU2007333098A1 (en) 2006-12-14 2008-06-19 Medarex, Inc. Human antibodies that bind CD70 and uses thereof
CN101605906A (zh) 2006-12-14 2009-12-16 梅达雷克斯公司 结合cd70的人类抗体及其用途
CA2947292C (en) 2006-12-27 2019-07-23 Emory University Compositions and methods for the treatment of infections and tumors
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
EP3124497B1 (en) 2007-09-14 2020-04-15 Adimab, LLC Rationally designed, synthetic antibody libraries and uses therefor
US20100233176A1 (en) 2008-10-06 2010-09-16 Cashman Neil R Methods and systems for predicting misfolded protein epitopes
BR112012006388B1 (pt) 2009-09-22 2022-01-04 Probiogen Ag Método para produzir uma molécula, e, método para produzir uma proteína
KR102024922B1 (ko) 2010-07-16 2019-09-25 아디맵 엘엘씨 항체 라이브러리
UA112170C2 (uk) 2010-12-10 2016-08-10 Санофі Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб
JOP20210044A1 (ar) * 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
GB201302447D0 (en) 2013-02-12 2013-03-27 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
WO2014144865A2 (en) 2013-03-15 2014-09-18 Genentech, Inc. Anti-crth2 antibodies and methods of use
JP6775422B2 (ja) * 2014-03-28 2020-10-28 ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． Ｃｄ３８及びｃｄ３に結合する二重特異性抗体
MA40894A (fr) 2014-11-04 2017-09-12 Glenmark Pharmaceuticals Sa Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production
BR112017011556A2 (en) 2014-12-01 2018-03-06 The Trustees Of The University Of Pennsylvania methods for generating a synthetic antibody, preventing or treating a disease, treating a subject of pathogen infection and a subject with cancer, product, nucleic acid molecule, and composition.
CN113527495A (zh) 2015-04-08 2021-10-22 索伦托药业有限公司 与cd38结合的抗体治疗剂
GB201506389D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
HRP20240338T1 (hr) 2015-06-24 2024-05-24 Janssen Biotech, Inc. Imunomodulacija i liječenje solidnih tumora s protutijelima koja se specifično vežu na cd38
JP7628764B2 (ja) 2015-09-29 2025-02-12 アムジエン・インコーポレーテツド Ａｓｇｒ阻害剤
BR112018002570A2 (pt) 2015-10-02 2018-10-16 Hoffmann La Roche molécula de ligação ao antígeno biespecífica, anticorpo biespecífico, polinucleotídeos, anticorpo que se liga especificamente ao ox40, composição farmacêutica e método para inibir o crescimento de células tumorais em um indivíduo
US12590171B2 (en) 2019-09-27 2026-03-31 Nanjing GenScript Biotech Co., Ltd. Anti-VHH domain antibodies and use thereof

Also Published As

Publication number Publication date
US11236173B2 (en) 2022-02-01
AU2018316522A1 (en) 2020-03-05
JP7299873B2 (ja) 2023-06-28
KR102770110B1 (ko) 2025-02-20
NZ761838A (en) 2025-03-28
EP3668543A1 (en) 2020-06-24
US20200362050A1 (en) 2020-11-19
KR20200036861A (ko) 2020-04-07
CN111032086B (zh) 2023-09-26
CN111032086A (zh) 2020-04-17
JP2020533965A (ja) 2020-11-26
WO2019034753A1 (en) 2019-02-21
AU2018316522B2 (en) 2025-02-20
US12162949B2 (en) 2024-12-10
US20220135697A1 (en) 2022-05-05
CA3072296A1 (en) 2019-02-21

Similar Documents

Publication Publication Date Title
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201810927QA (en) Pd-l1-specific antibodies and methods of using the same
SG11202000321PA (en) Cd38 modulating antibody
SG11201803956UA (en) Anti-dr5 antibodies and methods of use thereof
SG11201903857UA (en) Antibodies to pd-1 and uses thereof
SG11201806992VA (en) Antibodies to tigit
SG11201908056QA (en) Anti-par2 antibodies and uses thereof
SG11201810933QA (en) Anti-c5 antibodies and uses thereof
SG11201906853QA (en) Anti-rsv monoclonal antibody formulation
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201907848YA (en) Antibodies binding to vista at acidic ph
SG11201900885VA (en) Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
SG11201908578YA (en) Fc-optimized anti-cd25 for tumour specific cell depletion
SG11201906961UA (en) Polypeptide variants and uses thereof
SG11201809064QA (en) Chimeric neurotoxins
SG11201903454VA (en) Immunologically discernible cell surface variants for use in cell therapy
SG11201901899PA (en) Bispecific trivalent antibodies binding to claudin6 or claudin18.2 and cd3 for treatment of claudin expressing cancer diseases
SG11201907889YA (en) Glycan-interacting compounds and methods of use
SG11201806496SA (en) Antigen binding proteins that bind pd-l1
SG11201811432WA (en) Rna for cancer therapy
SG11201808724SA (en) Anti-tim-3 antibodies and compositions
SG11201906386XA (en) Combination therapy involving diaryl macrocyclic compounds
SG11201810420YA (en) Antibodies to alpha-synuclein and uses thereof
SG11201903012RA (en) Anti-c1s antibodies and methods of use thereof
SG11201908326YA (en) Methods of treating neurodegenerative diseases